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Abstract
Background: Schönlein-Henoch purpura is a systemic vasculitis that affects vessels of a small
caliber and rarely reported in the literature.
Case presentation: We report on a 35-year-old woman who developed palpable purpura with
necrotizing cutaneous lesions on the lower limbs at 27 weeks of gestation. She also complained of
epigastric pain and arthralgias. Histologic examination of a skin biopsy showed leukocytoclastic
vasculitis with intravascular fibrin thrombi. The direct immunofluorescence analysis evidenced
vascular deposits of IgA and C3 in the upper and mid-dermis. These findings were consistent with
Schönlein-Henoch purpura. There was no evidence of renal involvement or placental dysfunction.
The patient was treated with low-dose oral corticosteroids and a healthy infant was delivered by
cesarean section. Examination of the placenta and the navel string disclosed no signs of vasculitis
or infarction.
Conclusions: Schönlein-Henoch purpura is rarely reported in pregnancy. Treatment with orally
administred corticosteroids may lead to a beneficial outcome for mother and newborn.
Background
Schönlein-Henoch purpura (SHP) is a systemic vasculitis
that affects vessels of a small caliber [1]. The vascular pur-
pura is usually confined to the lower limbs and is associ-
ated, at varying degrees, with joint, gastrointestinal and
renal involvement [2].
In 1990, the American College of Rheumatology defined
SHP by the presence of 2 ore more of the following crite-
ria: age of disease onset (20 years or younger); palpable
purpura; acute abdominal pain and granulocytic infiltra-
tion in the walls of arterioles or venules [3]. Focusing on
the pathogenic role of IgA immune complexes in SHP, the
Chapel Hill Consensus Group view the diagnosis as a
small vessel vasculitis with predominant IgA vascular de-
posits [4]. SHP was first defined and is more commonly
reported in children. There is a peak incidence between 2
and 5 years of age. Boys are more frequently affected. The
incidence of SHP in the 2 to 14-year-old population is
about 14 cases out of 100 000 per year [5]. The onset of
SHP during pregnancy is very rare. Using an electronic lit-
erature research of MEDLINE and the National Library of
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tients with SHP in pregnancy exclusively in Journals for
gynecology, internal medicine, pathology, pediatric and
general medicine respectively, from 1976 to the present.
Therefore, we report on a patient who developed SHP at
27 weeks of gestation with successful outcome for mother
and child.
Case presentation
A 35-year-old unipara in the 31st week of gestation was
admitted with a 4 week history of purpura on the legs. She
also complained of epigastric pain and arthralgias, mainly
in the knees.
Examination revealed crops of non tender palpable pur-
pura on the legs, 1 to 3 mm in diameter (Fig 1). On the
anterior aspects of the lower legs, the lesions subsequently
coalesced to large plaques with a necrotic ulcerating cent-
er. A few scattered purpuric lesions were present on the ab-
domen.
Biopsy of a skin lesion showed leukocytoclastic vasculitis
(Fig 2 and Fig 3) with intravascular fibrin thrombi. The di-
rect immunofluorescence analysis evidenced vascular de-
posits of IgA and C3 in the upper and mid-dermis. These
findings, together with the gastrointestinal and articulary
symptoms, led to the diagnosis of Schönlein-Henoch pur-
pura.
Laboratory data were: red blood cell count 3,14 T/l, hemo-
globin 9,8 g/dl, hematocrit 29,1%, white blood cell count
9,96 G/l, platelets 236 G/l, ESR 84/94 mm, serum creati-
nine 0,73 mg/dl and urea 7 mg/dl. Liver parameters and
electrolytes were within normal range. Repeated urinanal-
ysis showed no proteinuria or haematuria. Stool guaiacs
were repeatedly negative.
Findings from the following tests were negative or within
normal range: antinuclear antibodies, ANCA, C3, C4, an-
tiphospholipid antibodies, serum immunoglobulin A, M,
and G respectively, ASLO, virus serologies including hep-
atitis A, B and C. The circulating immuncomplexes were
slightly raised (1,89 µg/ml, normal < 1,5 µg/ml). The
gynecological examination showed an ultrasound-esti-
mated gestation age of 31 weeks with a normal blood flow
in the umbilical artery. The patient's blood pressure
ranged from 100/70 to 120/80 mm Hg. Because of the
necrotizing cutaneous lesions, treatment with low-dose
oral corticosteroids (methylprednisolon 20 mg/day, i.e.
0,25 mg/kg body weight) was started. The lesions rapidly
resolved and the corticosteroid dosage was tapered off
progressively. After one month, treatment was stopped.
Subsequent antepartum course was unremarkable. Re-
peated controls of kidney function and blood pressure
showed normal results. At 38 weeks of gestation, a healthy
male infant weighting 4100 g was delivered by cesarean
section.
Histologic examination of the placenta and the navel
string showed no vasculitis or infarction (Fig 4). Direct
immunofluorescence did not evidence deposits of immu-
noreactants.
Conclusions
Schönlein-Henoch purpura is a distinctive clinical syn-
drome. The skin lesions consist of recurrent purpuric pa-
pules, sometimes necrotizing, on the lower limbs. Spread
of the rash to the trunk seems to be a predictive factor for
renal involvement [6]. Initial symptoms may be accompa-
nied by fever. Histological examination discloses leuko-
cytoclastic vasculitis in the upper and mid-dermis. The
direct immunofluorescence analysis of fresh lesions
Figure 1
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older lesions, these immunoreactants may lack.
Arthralgias occur in up to two thirds of patients, usually
affecting knees and ankles. Arthritis is rarely observed [8].
Gastrointestinal symptoms are frequent, appearing usual-
ly at the beginning of the disease and last for a few days.
They include colicky pain, nausea, vomiting, diarrhea,
constipation and occult or gross gastrointestinal bleeding.
Endoscopic examination discloses an erosive-haemor-
rhagic gastroenteritis, most often in the duodenum [9].
During the acute course of SHP, neurological symptoms
may occur. Headache seems to be the most frequent
symptom, convulsions are rare [10]. The reported inci-
dence of nephritis associated with SHP varies according to
the population studied. Renal involvement occurs in 25 to
50% of children. The glomerulonephritis usually leads to
proteinuria and microhaematuria.
More rarely, a nephritic syndrome, macrohaematuria or
arterial hypertension appear [11]. Glomerular changes
consist of segmental and focal mesangial and/or endothe-
lial proliferation and diffuse mesangial IgA deposits. Al-
though acute renal failure is rare, end-stage renal disease
may develop after a long latency period of up to 20 years
after diagnosis of SHP [12]. This indicates that careful
clinical and laboratory supervision is necessary even after
complete healing of skin lesions. If the kidneys are spared,
prognosis of SHP is excellent. Relapses of purpura, ab-
dominal pain and arthralgias occur over 3 to 6 weeks be-
fore resolution of the disease.
SHP in adulthood differs from the pediatric form of the
disease. Adults have more pronounced and chronic skin
lesions [13] and renal involvement is more frequent and
severe than in childhood [14]. However, long term out-
come of SHP seems equally good in patients of both age
groups [6,14].
Occurrence of SHP during pregnancy is exceptional. To
the best of our knowledge, nine cases have previously
been reported. Four patients were already known to have
SHP before pregnancy [15–18]. Three woman developed
SHP for the first time during gestation, at 11, 17 and 23
weeks respectively [19–21]. In two patients, diagnosis was
made in the post-partum period [22,23].
Symptomatology of SHP in pregnant woman has no spe-
cific characteristics. Diagnosis may be difficult when re-
nal, articular or gastrointestinal involvement preceed the
cutaneous manifestations since many aspects of SHP may
masquerade as preeclampsia or eclampsia, especially hy-
pertension, nephrotic syndrome, abdominal pain, head-
ache and convulsions.
The effect of pregnancy on the course of preexistant SHP
remains to be evaluated. Analysis of the four observations
reported in the literature shows: aggravation of the disease
Figure 2
Leucocytoclastic vasculitis in the upper and mid-dermis.
Asterisk marks the area of higher magnification (Fig 2b).
Figure 3
Leucocytoclastic vasculitis. Fibrin thrombi (large arrow) in
the lumen of the vessel featuring a destroyed wall. Note the
nuclear dust in a perivascular arrangement (small arrows).Page 3 of 5
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patient [16] and total disparition of symptoms in one pa-
tient [18]. The only obstetrical complication of SHP relat-
ed in the literature is pregnancy-induced hypertension
and its possible consequences (preeclampsia, eclampsia).
If kidneys are spared, obstetrical prognosis is good. There
is probably no risk of IgA vasculitis in the fetus as these
immunoglobulins cannot cross the normal placenta. Ex-
amination of the placenta in one case showed no vasculi-
tis or infarction [17] and this observation was confirmed
in our patient.
The pathogenesis of SHP remains poorly understood. The
similarity of the histologic findings in SHP to those of
Arthus reaction suggest an immune-complex mediated
disorder [24]. It is postulated that various antigenic stim-
uli cause elevation of circulating IgA and that complement
activation leads to necrotizing vasculitis. SHP has been re-
ported after bacterial infections (β-hemolytic Streptococ-
cus, Legionella, Salmonella, Helicobacter pylori, etc)
[25,26], viral infections (Hepatitis A and B, EBV, Parvovi-
rus, etc) [27,28], vaccinations (influenza) [29] and intake
of drugs (Penicillin, acetylsalicylic acid, enalapril, etc)
[30,31].
The efficacy of corticosteroids and immunsuppressants
(azathioprine, cyclophosphamide) in the treatment of
SHP is subject to controversy, especially when the kidneys
are involved [32]. Some cases of SHP were successfully
treated by dapsone or plasmapheresis [17,33]. Little expe-
rience exists concerning treatment of SHP during pregnan-







Written consent was obtained from the patient for publication of the pa-
tient's details. We acknowledge the excellent technical assistance of Bar-
bara Brückler.
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